Icon

SYNDROS - (5 mg/ml; Solution, Oral)

DRONABINOL Insys Therapeutics
5 mg/ml; Solution, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
None None
None None
Indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS); and. nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments
Yes
**** ***** ** ** *** **** ** ****** **** ******** ** ***, ****. ****** **** **** *** ****** **** ** ************* ** *******, ******* (**** ******** ** *** *, ****) - ** *******. ****** *** ****** ** ** ****** **** ********** *** ********* **** **** & ***** ***** *** ***** ** ********* *** *** *****. ***** ****** *** *** ******* ** ******* *** ****. ** ****** **** ** ****** ** ****** *** ***** ** ****** *** ****** *****. ***** ** *** **** ** ********* *** ********* ******* ********* ******* * **** ***** ********* ** $****.
SYNDROS Patent 1 Patent 2 Patent 3
**** ****** ******* ******* *******
***** ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** ****** *** \ ********* *** *, **** ******* **** *** ****** *** ****
***** ** \ ** ***** **, **** ******* **** ***** ***
  1. *** **, **** : **** ******** ***** ********* **** ** ************* ** *******, ******* (**** ******** ** *** *, ****) - ** *******.
  2. *** *, **** : ***** **** **** ** ** ** *** ****.
  3. *** **, **** : ***** ***** * **** ******* ***** ** ***** ***** **** ** **** ******* *******, ******* (**** ******** ** *** *, ****) - ** *******.
  4. *** **, **** : ********** ********* **** **** ***** *** ***** ** ********* *** *** *****.
  5. *** **, **** : ********** ********* **** ***** *** *** *** ******* ** **** ***** *** ***** ** ********* *** *** *****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.